According to a study that performed a functional analysis of single-nucleotide variants in the BRCA2 DBD domain using the saturation genome editing approach, missense mutations predicted to be pathogenic were associated with a higher frequency of LOH and an increased risk of breast and ovarian cancers.31 However, similar to the current study, only about 4% of the ClinVar VUS were reclassified as pathogenic, while most were reclassified as benign. The gene discussed is BRCA2; the disease is ovarian carcinoma.